Cue Biopharma, Inc. CUE shares are trading lower on Tuesday. The company reported 2024 fiscal-year earnings on Monday after ...

With the CSF-1R inhibitor space heating up, Germany's Merck Group has gone all-in on pimicotinib, paying Abbisko Therapeutics ...

Research and development expenses were $36.3 million and $40.8 million for the years ended December 31, 2024 and 2023, respectively. The decrease was primarily due to decreases in clinical trial costs ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Ono Pharmaceutical Co. Ltd. has entered into a drug discovery collaboration agreement with Reborna Biosciences Inc. to generate RNA-targeting novel small molecules in the field of the central nervous ...

Learn more about whether Alvotech or Merus N.V. is a better investment based on AAII's A+ Investor grades, which compare both ...

Equillium’s phase 3 graft-versus-host disease (GVHD) trial has missed its primary endpoint and two key secondary objectives.

Singapores manufacturing sector unexpectedly contracted in February, with output falling 1.3% year-on-year, defying forecasts ...

Some of the key insights of the Viscosupplementation Devices Market Report: • The viscosupplementation devices market, valued ...

Below, check out the roundup of California Healthline’s coverage. For today's national health news, read KFF Health News’ Morning Briefing.

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...